Investigational drug · Phase 3
MN-166
Also called: ibudilast
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
23
Any phase or sponsor naming "MN-166"
First trial start
2020
May 28, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MN-166", any sponsor or status.
- Phase 216
Conditions studied
As listed on its trial records.
- Amyotrophic Lateral Sclerosis
Approved drugs for the same conditions: ALS (amyotrophic lateral sclerosis) · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "MN-166" as an intervention, largest first.
- RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative MedicinePivotal-lookingCompleted
University Health Network, TorontoAcademic, hospital or other
NCT05513560 · 460 participants · Start May 31, 2023 · Primary completion Mar 31, 2025
Drug: Ibudilast; Pentoxifylline · For: Long COVID; Post COVID Condition; Post Acute Sequelae of COVID-19
Sites: Ottawa, Canada; Toronto, Canada · 3 sites in all
- Regeneration in Cervical Degenerative MyelopathyPivotal-lookingStatus unknown
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
NCT04631471 · 400 participants (planned) · Start Dec 22, 2021 · Primary completion Sep 1, 2026
Drug: Ibudilast; Matching placebo · For: Myelopathy; Spinal Cord Diseases
Sites: Cambridge, United Kingdom
- Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple SclerosisPivotal-lookingCompleted
MediciNovaIndustry
NCT01982942 · 255 participants · Start Nov 2013 · Primary completion May 2017
Drug: ibudilast; Placebo oral capsule · For: Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive
Sites: Birmingham, Alabama; Davis, California; Los Angeles, California · 28 sites in all
- Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSPivotal-lookingActive, not recruiting
MediciNovaIndustry
NCT04057898 · 234 participants · Start May 28, 2020 · Primary completion Apr 2027
Drug: MN-166; placebo · For: Amyotrophic Lateral Sclerosis
Sites: Orange, California; Jacksonville, Florida; Augusta, Georgia · 16 sites in all
- Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine UsersPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT03341078 · 176 participants · Start May 1, 2019 · Primary completion Oct 15, 2025
Drug: Ibudilast; Placebo Oral Tablet · For: Methamphetamine-dependence
Sites: Portland, Oregon
- Trial of Ibudilast for Methamphetamine DependencePivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT01860807 · 125 participants · Start Jul 2013 · Primary completion Dec 31, 2017
Drug: Ibudilast; Placebo · For: Methamphetamine Dependence; HIV Infection
Sites: Los Angeles, California
- Ibudilast for the Treatment of Alcohol Use DisorderPivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT03594435 · 102 participants · Start Oct 1, 2018 · Primary completion Apr 19, 2023
Drug: Ibudilast; Placebo oral capsule · For: Alcohol Use Disorder
Sites: Los Angeles, California
MediciNovaIndustry
NCT02238626 · 70 participants · Start Sep 2014 · Primary completion Aug 2017
Drug: Placebo (for MN-166); MN-166 and 1 more · For: Amyotrophic Lateral Sclerosis
Sites: Charlotte, North Carolina
- Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent GlioblastomaCompleted
MediciNovaIndustry
NCT03782415 · 64 participants · Start Dec 29, 2018 · Primary completion Aug 7, 2023
Drug: MN-166; Temozolomide · For: Glioblastoma; Recurrent Glioblastoma; GBM and 1 more
Sites: Boston, Massachusetts
University of California, Los AngelesAcademic, hospital or other
NCT03489850 · 52 participants · Start Jul 16, 2018 · Primary completion Mar 31, 2020
Drug: Ibudilast · For: Alcohol Use Disorder
Sites: Los Angeles, California
Newest research
PubMed records naming it or its code names, newest first.
- Corrigendum to 'Nicotinamide riboside, pterostilbene and ibudilast protect motor neurons and extend survival in ALS mice'.
Lo'pez-Blanch R, Salvador-Palmer R, Oriol-Caballo M, et al. · Neurotherapeutics 2026
- Synergistic modulation of cAMP and cGMP rescues hemin-induced plasma membrane fragmentation.
Laspa Z, Rohlfing AK, Fischer M, et al. · J Biol Chem 2026
- MIF-CD74 Signaling Defines a Brain-Specific Immune Vulnerability in Metastasis and Neurologic Disease.
Lee E, Kang Y · Cancer Res 2026
- MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders.
Alvaro-Espinosa L, Marquez-Galera A, Priego N, et al. · Cancer Res 2026
- Six promising drug repurposing candidates for Alzheimer's disease and their sex-specific mechanisms and efficacy.
Figueiredo-Pereira ME, Serrano PA, Rockwell P · Neural Regen Res 2026
- Therapeutic Effects of Combined 6-Shogaol and Ibudilast on Neuroinflammation and Behavioral Deficits in a Cuprizone Mouse Model of Multiple Sclerosis.
Alshahrany GA, Alyami KA, Alzahrani NA, et al. · Pharmaceuticals (Basel) 2026
Also in development for Amyotrophic Lateral Sclerosis
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- PridopidinePhase 32 trials
Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease
- ION363Phase 31 trial
Ionis Pharmaceuticals · Amyotrophic Lateral Sclerosis
- CNMAu8gold nanocrystalsPhase 22 trials
Clene Nanomedicine · Amyotrophic Lateral Sclerosis, Multiple Sclerosis
- AMT-162Phase 21 trial
UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis
- AP-101Phase 21 trial
AL-S Pharma · Amyotrophic Lateral Sclerosis
- BIIB147Phase 21 trial
Biogen · Amyotrophic Lateral Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.